Plasma Fractionation Market Challenges Associated with Increasing Adoption of Recombinant Therapies

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Plasma Fractionation Market- (By Product (Immune-Globulins(Intravenous Immune-Globulins, Subcutaneous Immune-Globulins, Other Immune-Globulins), Coagulation Factor Concentrates (Factor VIII, Factor IX, Von Willebrand Factor, Prothrombin Complex Concentrate, Fibrinogen Concentrates, Factor XIII, Others), Albumin, Protease Inhibitors, Other Plasma Products), By Application (Neurology, Immunology, Hematology, Critical Care, Pulmonology, Hemato-Oncology, Rheumatology, Others), By End-User (Hospitals & Clinics, Clinical Research Laboratories, Academic Institutes)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Plasma Fractionation Market is valued at USD 4.2 Bn in 2023, and it is expected to reach USD 8.9 Bn by the year 2031 with a CAGR of 10.1% during a forecast period of 2024-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2140

Plasma fractionation is a highly specialized bioprocess that involves the separation and purification of individual proteins from human plasma-the liquid component of blood-to manufacture clinically essential therapies such as albumin, immunoglobulins, and coagulation factors. These plasma-derived products are indispensable in the treatment of a wide range of medical conditions, particularly immunodeficiency disorders, hematological conditions, and other rare or chronic diseases.

The global plasma fractionation market is experiencing robust growth, primarily driven by the expanding geriatric population, which is more susceptible to chronic and rare illnesses requiring plasma-based treatments. Increasing clinical demand for immunoglobulins and alpha-1 antitrypsin across diverse therapeutic areas is further accelerating market expansion. In addition, the continuous growth of plasma collection infrastructure worldwide is improving supply chain efficiency and production capacity. Supportive government initiatives aimed at increasing awareness of the therapeutic importance of plasma-derived products are also expected to sustain market growth over the forecast period.

Prominent Players in the Plasma Fractionation Market:
• CSL (Australia)
• Takeda Pharmaceutical Company Limited (Japan)
• Grifols, S.A. (Spain)
• Octapharma AG (Switzerland)
• Kedrion S.P.A (Italy)
• LFB (France)
• ADMA Biologics (US)
• Sanquin (Netherlands)
• China Biologic Products Holdings Inc. (China)
• GC Pharma (Korea)
• Hualan Bioengineering Co., Ltd. (China)
• Japan Blood Products Organization (Japan)
• Emergent BioSolutions (US)
• Shanghai Raas Blood Products Co., Ltd. (China)
• Intas Pharmaceuticals Ltd. (India)
• Bharat Serum Vaccines Limited (India)
• SK Plasma (Korea)
• Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China)
• Kamada (Israel)
• Centurion Pharma (Istanbul)
• Prothya Biosolutions (Netherlands)
• PlasmaGen BioSciences Pvt. Ltd. (India)
• Virchow Biotech Private Limited (India)
• Fusion Healthcare (India)
• Hemarus Therapeutics Limited (India)
• Others

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-01

Market Dynamics
Drivers:
The increasing incidence of immunodeficiency disorders remains a key catalyst for growth in the plasma fractionation market. Rising global demand for plasma-derived therapeutics-most notably immunoglobulins-is significantly contributing to market expansion. In response, major industry stakeholders are increasing investments in research and development to advance novel plasma-based therapies. Furthermore, strategic acquisitions and capacity expansions of plasma collection centers are being pursued to enhance supply chain stability and ensure a reliable supply of source plasma. The continued global rise in immunodeficiency-related conditions is expected to sustain long-term demand for plasma-derived products.

Challenges:
A notable constraint on market growth is the expanding use of recombinant therapies, which are increasingly favored in clinical practice due to their reduced immunogenicity and proven efficacy in preventive treatment regimens. These alternatives offer clinical advantages such as prolonged half-life, lower administration frequency, and improved prophylactic outcomes. Consequently, the growing preference for recombinant products is gradually reducing reliance on conventional plasma-derived therapies.

Regional Trends:
The Asia-Pacific region is anticipated to account for a significant share of the global plasma fractionation market and is expected to register strong growth during the forecast period. This expansion is supported by the presence of leading industry participants actively engaged in the development and commercialization of advanced plasma-derived products. Meanwhile, North America-particularly the United States-is projected to maintain steady market growth, driven by its well-established plasma fractionation infrastructure, extensive plasma collection network, and strong production capabilities.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2140

Recent Developments:
• In March 2023, Takeda made an investment of 100 billion JPY in the establishment of a novel manufacturing facility in Japan, specifically dedicated to the production of plasma-derived medicines. The investment made by Takeda exemplified the company's dedication to prioritising patients and fulfilling its obligations in relation to its patient-centric, people-oriented, and environmentally conscious objectives. This approach was supported by the utilisation of data and digital technologies.
• In Dec 2022, CSL has recently inaugurated its Plasma Fractionation Facility in Victoria, Australia, which represents a significant milestone in the country's plasma manufacturing sector. With a staggering investment of $900 Bn, this state-of-the-art facility stands as the largest of its type in the Southern Hemisphere. The aforementioned statement pertains to a capital investment programme of over $2 billion that CSL is presently implementing in Australia.

Segmentation of Plasma Fractionation Market-
By Product-
• Immune-Globulins
o Intravenous Immune-Globulins
o Subcutaneous Immune-Globulins
o Other Immune-Globulins
• Coagulation Factor Concentrates
o Factor VIII
o Factor IX
o Von Willebrand Factor
o Prothrombin Complex Concentrate
o Fibrinogen Concentrates
o Factor XIII
o Others
• Albumin
• Protease Inhibitors
• Other Plasma Products
By Application-
• Neurology
• Immunology
• Hematology
• Critical Care
• Pulmonology
• Hemato-Oncology
• Rheumatology
• Others
By End-User-
• Hospitals & Clinics
• Clinical Research Laboratories
• Academic Institutes
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/plasma-fractionation-market/2140

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.